World Health Organization. Global vaccine action plan 2011–2020. WHO. https://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/ (2013). Accessed Oct 2022.

World Health Organization. Child mortality and causes of death. WHO. https://www.who.int/gho/child_health/mortality/mortality_under_five_text/en/ (2020). Accessed Oct 2022.

Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945–6. https://doi.org/10.1126/science.abb8923.

Article  CAS  PubMed  Google Scholar 

Forni G, Mantovani A. COVID-19 Commission of Accademia Nazionale dei Lincei, Rome COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28(2):626–39. https://doi.org/10.1038/s41418-020-00720-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21:83–100. https://doi.org/10.1038/s41577-020-00479-7.

Article  CAS  PubMed  Google Scholar 

• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15. https://doi.org/10.1056/NEJMoa2034577. This article demonstrates the mechanism of action, safety and efficacy of the Pfizer-BioNTech vaccine against COVID19.

Article  CAS  PubMed  Google Scholar 

• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2— preliminary report. N Engl J Med Overseas Ed. 2020;383:1920–31. https://doi.org/10.1056/NEJMoa2022483. This article discusses the mechanism of action and rate of adverse events of the Moderna vaccine against COVID19.

• Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187–201. https://doi.org/10.1056/NEJMoa2101544. This article elaborates on the mechanism of action, efficacy and adverse events with the Ad26.COV2.S vaccine.

Article  CAS  PubMed  Google Scholar 

• Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887–97. https://doi.org/10.1016/S0140-6736(20)31866-3. Article discussing the principle of the Sputnik V vaccine along with phase III trial data regarding efficacy and tolerability.

• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. https://doi.org/10.1016/S0140-6736(20)32661-1. Article elucidating the phase II/III clinical trial data regarding vaccine efficacy and adverse event profile in the Oxford/ ChAdOx1 nCoV-19 vaccine.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172–83. https://doi.org/10.1056/NEJMoa2107659. Data from Phase III trial of Novavax including protection offered and adverse event profile.

Article  CAS  PubMed  Google Scholar 

• Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173–84. https://doi.org/10.1016/S0140-6736(21)02000-6. This article elucidates the mechanism of action, and reports the efficacy and safety data of phase III trial with Covaxin.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111:219–26. https://doi.org/10.1016/j.ijid.2021.08.013. This article reviews the adverse events reported with the Sinopharm vaccine use in the UAE.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803–12. https://doi.org/10.1016/S1473-3099(20)30987-7. Article discussing potency and side effect profile of CoronaVac vaccine.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36(4):427–39. https://doi.org/10.1007/s12291-021-00968-z. This article provides a comprehensive review of the safety profile of the various licensed COVID19 vaccines.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganesan S, Al Ketbi LMB, Al Kaabi N, Al Mansoori M, Al Maskari NN, Al Shamsi MS, et al. Vaccine side effects following COVID-19 vaccination among the residents of the UAE-an observational study. Front Public Health. 2022;10:876336. https://doi.org/10.3389/fpubh.2022.876336.

Article  PubMed  PubMed Central  Google Scholar 

• Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI, et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ. 2022;378:e069445. https://doi.org/10.1136/bmj-2021-069445. Article reviews available data regarding development of myocarditis and pericarditis post-COVID vaccination and possible mechanism.

Article  PubMed  Google Scholar 

•• Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2022;43(1):3–40. https://doi.org/10.1007/s10072-021-05662-9. An exhaustive review of reported neurological adverse events with various COVID19 vaccines.

Article  PubMed  Google Scholar 

•• García-Grimshaw M, Ceballos-Liceaga SE, Hernández-Vanegas LE, Núñez I, Hernández-Valdivia N, Carrillo-García DA, et al. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: a nationwide descriptive study. Clin Immunol. 2021;229:108786. https://doi.org/10.1016/j.clim.2021.108786. The article reports on the incidence of neurological adverse events post-vaccination with the first dose of Pfizer-BioNTech vaccine in a Mexican cohort.

Kim SH, Wi YM, Yun SY, Ryu JS, Shin JM, Lee EH, et al. Adverse events in healthcare workers after the first dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccination: a single center experience. J Korean Med Sci. 2021;36(14):e107. https://doi.org/10.3346/jkms.2021.36.e107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S, et al. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J Korean Med Sci. 2021;36(21):e153. https://doi.org/10.3346/jkms.2021.36.e153.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Göbel CH, Heinze A, Karstedt S, Morscheck M, Tashiro L, Cirkel A, et al. Headache attributed to vaccination against COVID-19 (coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study. Pain Ther. 2021;10(2):1309–30. https://doi.org/10.1007/s40122-021-00296-3.

Article  PubMed  PubMed Central  Google Scholar 

• García-Azorín D, Do TP, Gantenbein AR, Hansen JM, Souza MNP, Obermann M, et al. Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis. J Headache Pain. 2021;22(1):108. https://doi.org/10.1186/s10194-021-01324-5. This article provides strong evidence in favor of ruling out cerebral venous sinus thrombosis in patients with delayed onset headaches after adenoviral vaccines.

Article  CAS  PubMed  PubMed Central  Google Scholar 

World Health Organization. COVID-19 vaccines: safety surveillance manual. World Health Organization. 2020. https://apps.who.int/iris/handle/10665/338400. Accessed Oct 2022.

•• Iba T, Levy JH, Warkentin TE. Recognizing vaccine-induced immune thrombotic thrombocytopenia. Crit Care Med. 2022;50(1):e80–6. https://doi.org/10.1097/CCM.0000000000005211. This article provides an extensive review of vaccine-induced thrombocytopenia following COVID19 vaccination.

Article  CAS  PubMed  Google Scholar 

•• Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2104840. The authors of this study demonstrated their patients to test positive on a screening platelet factor 4 (PF4)-heparin immunoassay although none of them had received heparin in the past. Patients also tested positive on a platelet-activation assay in the presence of PF4 independent of heparin. Platelet activation was inhibited by high levels of heparin and immunoglobulin . It was postulated that “the vaccine resulted in a rare thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia (HIT)”.

Article  PubMed  PubMed Central  Google Scholar 

•• Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(23):2202–11. https://doi.org/10.1056/NEJMoa2105385. Case series of patients who developed thrombosis with thrombocytopenia and positive antibodies to platelet factor 4 after inoculation with AstraZeneca vaccine, providing insights into mechanism and outcomes.

Article  CAS  PubMed  Google Scholar 

Bersinger S, Lagarde K, Marlu R, Pernod G, Payen JF. Using nonheparin anticoagulant to treat a near-fatal case with multiple venous thrombotic lesions during ChAdOx1 nCoV-19 vaccination-related vaccine-induced immune thrombotic thrombocytopenia. Crit Care Med. 2021;49(9):e870–3. https://doi.org/10.1097/CCM.0000000000005105.

Article  CAS  PubMed  Google Scholar 

Graf T, Thiele T, Klingebiel R, Greinacher A, Schäbitz WR, Greeve I. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus nvenous and portal vein thrombosis. J Neurol. 2021:20211–3. https://doi.org/10.1007/s00415-021-10599-2

George G, Friedman KD, Curtis BR, Lind SE. Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination. Am J Hematol. 2021. https://doi.org/10.1002/ajh.26237.

Tiede A, Sachs UJ, Czwalinna A, Werwitzke S, Bikker R, Krauss JK, et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood. 2021;138(4):350–3. https://doi.org/10.1182/blood.2021011958.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schulz JB, Berlit P, Diener HC, Gerloff C, Greinacher A, Klein C, et al. COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. Ann Neurol. 2021;90(4):627–39. https://doi.org/10.1002/ana.26172.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gattringer T, Gressenberger P, Gary T, Wölfler A, Kneihsl M, Raggam RB. Successful management of vaccine-induced immune thrombotic thrombocytopenia-related cerebral sinus venous thrombosis after ChAdOx1 nCov-19 vaccination. Stroke Vasc Neurol.svn-2021–001142. 2021. https://doi.org/10.1136/svn-2021-001142

Clark RT, Johnson L, Billotti J, Foulds G, Ketels T, Heard K, et al. Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination. Ann Emerg Med. 2021;78(4):511–4. https://doi.org/10.1016/j.annemergmed.2021.04.035.

Article  PubMed  PubMed Central  Google Scholar 

•• Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114. https://doi.org/10.1136/bmj.n1114. Study reporting arterial and hemostatic events after AstraZeneca vaccination in Denmark and Norway.

Article  PubMed  Google Scholar 

Krzywicka K, Heldner MR, Sánchez van Kammen M, van Haaps T, Hiltunen S, Silvis SM, et al. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. Eur J Neurol. 2021;28(11):3656–62. https://doi.org/10.1111/ene.15029.

Article  PubMed  PubMed Central  Google Scholar 

McKeigue PM, Burgul R, Bishop J, Robertson C, McMenamin J, O’Leary M, et al. Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland. BMC Infect Dis. 2021;21(1):1275. https://doi.org/10.1186/s12879-021-06960-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicen